(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress considers passing misguided proposals in the new year that will undermine the critical flexibility and
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. All that Glitters is Not Gold… It’s true,
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote in the Senate Finance Committee to advance legislation impacting the Medicare Part D program and pharmacy benefit companies, or PBMs, that threatens to undermine
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you missed it, the Coalition for Affordable Prescription Drugs (CAPD), an organization that represents a diverse
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. Set the Record Straight on Supreme Court’s PBM
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing their pharmacy benefits. From formularies to compensation, there are choices for employers and plans to
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. The Latest in Rx News: Why are insulin prices so high?
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
According to government estimates, the opioid epidemic has reached crisis proportions, and now costs the US more than $500 billion annually. Of this total, $432 billion is from the total cost of fatalities and $72 billion is from non-fatality costs
©2024 PCMA. All Rights Reserved.
